特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
871451

注入式ドラッグデリバリー装置市場:成長率、傾向、および予測

Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
注入式ドラッグデリバリー装置市場:成長率、傾向、および予測
出版日: 2020年02月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは注入式ドラッグデリバリー装置市場について調査しており、市場概況や成長要因・阻害要因、装置タイプ・治療用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報をまとめています。

目次

第1章 イントロダクション

  • 研究成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 慢性疾患の罹患率の増加
    • 自己注射の需要増加につながる利点と利便性
    • 注射器の需要増加につながる生物製剤市場の成長
  • 市場阻害要因
    • 針によるけがと感染
    • 代替投与方法の使用の拡大
  • ポーターファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 装置タイプ別
    • 従来のドラッグデリバリー装置
    • 自己投与型ドラッグデリバリー装置
  • 治療用途別
    • 循環器疾患
    • 糖尿病
    • 腫瘍学
    • 自己免疫疾患
    • B型肝炎
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Alkermes
    • Baxter International, Inc.
    • Becton, Dickinson and Company
    • Eli Lilly and Company
    • Gerresheimer AG
    • Novartis AG
    • Pfizer, Inc.
    • Schott AG
    • テルモ株式会社
    • Teva Pharmaceutical Industries Ltd

第7章 市場機会および今後の動向

目次
Product Code: 52626

The injectable drug delivery devices market is expected to register a CAGR of nearly 11.5%, during the forecast period.

  • The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self injectors and growth of the biologics market, leading to increased demand for injectors.
  • The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.
  • A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.
  • Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.

Key Market Trends

Self-injectable Drug Delivery Devices is Anticipated to be Dominant during the Forecast Period

There have been boundless innovations and developments in self-injectable devices driving the growth of the market. The other major advantages associated with self-injectable injections are that they are found to be of convenient usage and low healthcare cost. These self-injectables were developed with the help of patient feedback, to provide the most adaptable devices, which have high precision of drug delivery, and are easy to use.

In addition to this, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied, during the forecast period.

The North America Region Dominates the Injectable Drug Delivery Devices Market

North America has been found dominating the injectable drug delivery devices, due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, and increase in government funding. Hence, all these factors are found associated with the growth of the market.

Competitive Landscape

The companies present in the market are found focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market shares. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Chronic Diseases
    • 4.2.2 Benefits and Convenience Leading to Increased Demand for Self Injectors
    • 4.2.3 Growth of the Biologics Market Leading to Increased Demand for Injectors
  • 4.3 Market Restraints
    • 4.3.1 Injuries and Infections Caused by Needles
    • 4.3.2 Growing Use of Alternative Delivery Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Devices Type
    • 5.1.1 Conventional Drug Delivery Devices
    • 5.1.2 Self-injectable Drug Delivery Devices
      • 5.1.2.1 Prefilled Syringes
      • 5.1.2.2 Injectable Pens
      • 5.1.2.3 Auto Injectors
      • 5.1.2.4 Needle-free Injectors
      • 5.1.2.5 Other Device Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Cardiovascular Disease
    • 5.2.2 Diabetes
    • 5.2.3 Oncology
    • 5.2.4 Autoimmune Disorders
    • 5.2.5 Hepatitis
    • 5.2.6 Other Therapeutic Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Gerresheimer AG
    • 6.1.5 Novo Nordisk A/S
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Schott AG
    • 6.1.8 Terumo Corporation
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 West Pharmaceutical Services Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.